Home > Insider Trading > Filing (0001144204-19-041520)

Filing Details

Accession Number:: 0001144204-19-041520
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2019-08-23 14:13:44
Reporting Period:: 2019-08-19

Accepted Time:: 2019-08-23 14:13:44
Original Submission Date:: 2019-08-21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1023024	Ani Pharmaceuticals Inc	ANIP	Pharmaceutical Preparations (2834)	582301143

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1109507	Meridian Venture Partners Ii Lp	259 N. Radnor-Chester Road Suite 130 Radnor PA 19087	No	No	Yes	No
1579672	Jr E. Robert Brown	C/O Ani Pharmaceuticals, Inc. 210 Main Street West Baudette MN 56623	Yes	No	No	No
1580169	Meridian Venture Partners Ii, Co.	259 N. Radnor-Chester Road Suite 130 Radnor PA 19087	No	No	Yes	No
1580170	Meridian Venture Partners Ii Gp, L.p.	259 N. Radnor-Chester Road Suite 130 Radnor PA 19087	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-08-19	2,067	$68.30	2,286,795	No	4	S	Direct
Common Stock	Disposition	2019-08-20	5,512	$68.18	2,281,283	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were sold pursuant to a Rule 10b5-1 diversification plan entered into by the Reporting Person on June 6, 2019. The shares were sold in multiple transactions at prices ranging from $68.00 to $69.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were sold pursuant to a Rule 10b5-1 diversification plan entered into by the Reporting Person on June 6, 2019. The shares were sold in multiple transactions at prices ranging from $68.00 to $68.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
Meridian Venture Partners II, Co. (MVP Corp.) is the general partner of Meridian Venture Partners II GP, L.P. (GP), the general partner of Meridian Venture Partners II, L.P. (MVP II). Robert E. Brown, Jr., a director of the issuer, is the President, sole stockholder and sole director of MVP Corp., as well as a limited partner of GP and one of two principals of MVP II.
This Form 4 Amendment is being filed for the sole purpose of reporting that sales under the Reporting Person's 10b5-1 diversification plan has completed, and no further sales will take place under the plan.